Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong

ConditionAging
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65+
SponsorHong Kong University of Science and Technology

About this trial

Population aging is changing societal dynamics and poses significant global challenges. By 2050, an estimated 1.6 billion people worldwide will be over age 65. Because aging is the primary risk factor for many common chronic diseases, it is essential to reduce the burden of age-related illnesses and promote healthy aging. Hong Kong has one of the largest proportions of elderly adults and has the highest life expectancy in the world, with approximately 11,575 centenarians reported in 2021. Thus, the long-lived population in Hong Kong is a valuable resource for studying healthy aging.

Longevity is a complex trait influenced by genetic, environmental, and behavioral factors. To unveil the mechanisms leading to longevity and healthy aging, researchers focused on centenarians who are extremely long living. Comparisons between long-lived individuals (LLIs) and others have identified several genetic factors and protein markers associated with longevity. Previous centenarian studies revealed that centenarians and their offsprings have a 5-fold lower risk of developing age-related diseases such as Alzheimer's disease and higher cognitive reserve. Certain protein signatures predict longer survival and centenarians acquire aging signatures much later than elderly in the general population. Certain healthy lifestyle leads to higher chance becoming centenarians, including never smoking, exercise and greater dietary diversity.

Despite emerging studies on centenarian population, an integrated approach to understand diverse molecular signatures of longevity is still lacking. Moreover, most of the centenarian studies are based on European descents. To conclude, a multi-omics study examining the genetic, proteomic, metabolomic, and microbiota profiles of LLIs in Chinese population is necessary.

Hence, the study proposed herein aims to identify multi-omics biomarkers that can be used to monitor aging processes and related diseases. In addition, it will provide candidate modifiable factors to promote healthy aging, focusing on Chinese population and local Hong Kong population for the first time. Ultimately, the insights gained from this research will inform the development of effective strategies to enhance healthy aging and improve the quality of life of our local aging population.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Han Chinese ethnicity

Able to provide official evidence for being 95 years or older (e.g., a birth certificate)

Mentally capable of consenting to join the study with or without informant presence

Consent to donation of biospecimens (i.e., blood)

Disqualifiers

Mentally incapable of consenting to join the study even with the presence of an informant

Refusal to provide blood samples

Trial population

Elderly with extreme longevity (aged \>=95 years old)

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Observational

    Other intervention

    Clinical profile, blood collection, cognitive assessment, questionnaires on modifiable risk factors

Treatment groups

2,500 Participants
are divided into 2 treatment groups
Group A: long-lived individuals (LLIs)1 intervention
Group B: Elderly controls1 intervention

Trial outcomes

Primary outcomes

1

Biobank of LLIs

A comprehensive cohort of LLIs with data on demographics, clinical profiles, cognitive and functional assessments, lifestyle, and genomic and proteomic biomarkers

Time frame
3-5 years
2

Genetic and modifiable factors associated with longevity

Genetic and modifiable factors associated with longevity

Time frame
3-5 years

Secondary outcomes

1

AI-based model

AI-based model to elucidate candidate modifiable factors that promote healthy aging

Time frame
5 years
2

Healthy aging strategies

Recommendations for personalized strategies to enhance healthy aging in the elderly population

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Hong Kong University of Science and Technology

Lead sponsor

Hong Kong Center for Neurodegenerative Diseases

Collaborator